



February 7th, 2011

TMRC Co., Ltd.

A Basic Agreement for business alliance of TM-411 in China

TMRC has concluded a Basic Agreement for business alliance of TM-411(Tamibarotene) on February 2, 2011 with a Japanese company, EPS Co., Ltd. (located in Bunkyo-Ku, Tokyo, Yan Hao, President & CEO) and a Japanese company, LOTUS Pharmaceutical Co., Ltd. ((located in Minato-Ku, Tokyo, Kihito Takahashi, President & CEO) to sell product (TM-411) for the treatment of acute promyelocytic leukemia (APL) in China. In September 2010, a permission of clinical trial was obtained from SFDA and clinical trial will be started from the beginning of 2011.

※Tamibarotene

Tamibarotene is a synthetic retinoid originally synthesized by the University of Tokyo, which was designed to improve chemical stability, safety and efficacy as compared with existing retinoid compounds, shows a strong differentiation induction activity.

TOKO Pharmaceutical Co. Ltd. has developed the product and obtained an approval for use in relapsed/refractory APL in April 11th, 2005 and marketed as “Amnolake[®] Tablet 2mg” in June, 2005 in Japan.

TMRC has been developing the product for APL through our licensing partner in U.S./Europe (CytRx Corporation: U.S.A.) and the product for hepatocellular carcinoma (HCC) through our licensing partner in Japan (ZERIA Pharmaceutical Co., Ltd.: Chuo-Ku, Tokyo).

• TMRC Co., Ltd.

Head office : 6-3, Nibancho, Chiyoda-ku, Tokyo 102-0084, JAPAN
Paid-in capital: Yen 50 Mil.
Representative: Hisao Ekimoto, Ph.D. (President &CEO)
Business activity: Development,Licensing and Marketing of innovative anti-cancer
Drugs
URL : <http://www.tmrc.co.jp/english/index.html>

• EPS Co., Ltd.

URL : <http://www.eps.co.jp/en/index.html>

• LOTUS Pharmaceutical Co., Ltd.

URL : <http://www.lotus-ltd.co.jp/>